{"id":116467,"date":"2025-04-25T08:33:08","date_gmt":"2025-04-25T16:33:08","guid":{"rendered":"https:\/\/xira.com\/p\/?p=116467"},"modified":"2025-04-25T08:33:08","modified_gmt":"2025-04-25T16:33:08","slug":"writing-strong-antibody-claims-avoiding-or-addressing-uspto-rejections-for-written-description-and-enablement","status":"publish","type":"post","link":"https:\/\/xira.com\/p\/2025\/04\/25\/writing-strong-antibody-claims-avoiding-or-addressing-uspto-rejections-for-written-description-and-enablement\/","title":{"rendered":"Writing Strong Antibody Claims: Avoiding or Addressing USPTO Rejections for Written Description and Enablement"},"content":{"rendered":"

Many patent applicants currently face difficulty in obtaining antibody claims because of written description and enablement rejections under 35 U.S.C. \u00a7112(a). The USPTO routinely rejects claims as too broad. The heightened disclosure requirements increase laboratory costs to generate sufficient data for a \u00a7112(a)-proof specification.<\/p>\n

\"\"<\/p>\n

\"\"<\/a>\u00a0\"\"<\/a>\u00a0\"\"<\/a>\u00a0\"\"<\/a>\u00a0\"\"<\/a>\u00a0\"\"<\/a>\u00a0\u00a0<\/div>\n

Many patent applicants currently face difficulty in obtaining antibody claims because of written description and enablement rejections under 35 U.S.C. \u00a7112(a). The USPTO routinely rejects claims as too broad. The heightened disclosure requirements increase laboratory costs to generate sufficient data for a \u00a7112(a)-proof specification.<\/p>\n

\"\"<\/p>\n

\"\"<\/a>\u00a0\"\"<\/a>\u00a0\"\"<\/a>\u00a0\"\"<\/a>\u00a0\"\"<\/a>\u00a0\"\"<\/a>\u00a0\u00a0<\/div>\n","protected":false},"excerpt":{"rendered":"

Many patent applicants currently face difficulty in obtaining antibody claims because of written description and enablement rejections under 35 U.S.C. \u00a7112(a). The USPTO routinely rejects claims as too broad. The heightened disclosure requirements increase laboratory costs to generate sufficient data for a \u00a7112(a)-proof specification. \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Many patent applicants currently face difficulty in obtaining antibody claims […]<\/p>\n","protected":false},"author":3,"featured_media":116468,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"_et_pb_use_builder":"","_et_pb_old_content":"","_et_gb_content_width":"","_jetpack_memberships_contains_paid_content":false,"footnotes":""},"categories":[23],"tags":[],"class_list":["post-116467","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-law-com"],"jetpack_featured_media_url":"https:\/\/i0.wp.com\/xira.com\/p\/wp-content\/uploads\/2025\/04\/legal-news-nZheb1.jpeg?fit=621%2C372&ssl=1","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/xira.com\/p\/wp-json\/wp\/v2\/posts\/116467","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/xira.com\/p\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/xira.com\/p\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/xira.com\/p\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/xira.com\/p\/wp-json\/wp\/v2\/comments?post=116467"}],"version-history":[{"count":1,"href":"https:\/\/xira.com\/p\/wp-json\/wp\/v2\/posts\/116467\/revisions"}],"predecessor-version":[{"id":116481,"href":"https:\/\/xira.com\/p\/wp-json\/wp\/v2\/posts\/116467\/revisions\/116481"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/xira.com\/p\/wp-json\/wp\/v2\/media\/116468"}],"wp:attachment":[{"href":"https:\/\/xira.com\/p\/wp-json\/wp\/v2\/media?parent=116467"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/xira.com\/p\/wp-json\/wp\/v2\/categories?post=116467"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/xira.com\/p\/wp-json\/wp\/v2\/tags?post=116467"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}